trending Market Intelligence /marketintelligence/en/news-insights/trending/k-w9PW_LNOwuODVaBfVM4Q2 content esgSubNav
In This List

Esperion Therapeutics prices $151.9M common stock offering

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Esperion Therapeutics prices $151.9M common stock offering

Esperion Therapeutics Inc. priced an underwritten public offering of 3.1 million common shares at $49 apiece, for expected gross proceeds of $151.9 million.

The company also granted underwriters a 30-day option to buy up to an additional 465,000 common shares.

The offering is expected to close on or around Aug. 15, subject to customary closing conditions.

Esperion plans to use net proceeds to help fund its CLEAR Outcomes cardiovascular outcomes trial, support regulatory submissions and pre-commercial launches andinitiate development activities. Proceeds will also be used for working capital and general corporate expenses.

Jefferies LLC, Cowen and UBS Investment Bank are acting as joint book-running managers for the offering, with JMP Securities, Stifel and Needham & Co. as co-managers.